Disc Medicine (IRON) closed at $80.00 on November 13, 2026, down 3.9% from the previous close, on volume of 755,185 shares (30-day average 1,349,015).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | 4 Leg Call/Put Combo Calendar | 16-Oct-2665 P|20-Nov-2660 C : 60 P : 70 C | 4,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Analysts’ Top Healthcare Picks: Asahi Intecc Co (AHICF), Disc Medicine (IRON)
TipRanks (Fri, 13-Nov 11:50 AM ET)
TipRanks (Tue, 10-Nov 3:20 AM ET)
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Immunic (IMUX)
TipRanks (Mon, 9-Nov 5:40 AM ET)
Disc Medicine’s Complementary Blood-Disorder Portfolio Supports Buy Rating and $132 Price Target
TipRanks (Mon, 9-Nov 4:26 AM ET)
Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 5-Nov 8:30 AM ET)
Globe Newswire (Wed, 4-Nov 9:05 AM ET)
Disc Medicine to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 2-Nov 8:30 AM ET)
Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock
Globe Newswire (Tue, 20-Oct 8:52 PM ET)
Globe Newswire (Mon, 19-Oct 4:01 PM ET)
Market Chameleon (Mon, 19-Oct 6:26 AM ET)
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Disc Medicine trades on the NASDAQ stock market under the symbol IRON.
As of November 13, 2026, IRON stock price declined to $80.00 with 755,185 million shares trading.
IRON has a beta of 1.03, meaning it tends to be more sensitive to market movements. IRON has a correlation of 0.05 to the broad based SPY ETF.
IRON has a market cap of $3.55 billion. This is considered a Mid Cap stock.
Last quarter Disc Medicine reported $0 in Revenue and -$1.53 earnings per share. This fell short of revenue expectation by $-250,000 and exceeded earnings estimates by $.17.
In the last 3 years, IRON traded as high as $99.50 and as low as $25.60.
The top ETF exchange traded funds that IRON belongs to (by Net Assets): IWM, VTI, XBI, IWO, VXF.
IRON has underperformed the market in the last year with a price return of -8.1% while the SPY ETF gained +13.4%. However, in the short term, IRON had mixed performance relative to the market. It has outperformed in the last 3 months, returning 0.0% vs -2.8% return in SPY. But in the last 2 weeks, IRON shares have been beat by the market, returning -1.0% compared to an SPY return of -0.2%.
IRON support price is $80.23 and resistance is $86.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRON shares will trade within this expected range on the day.
